An Act to amend and reenact § 32.1-65 of the Code of Virginia, relating to newborn screening; evaluation of disorders for inclusion.
HB433 amends Virginia’s newborn screening law to create a more structured process for adding disorders to the state’s required screening panel. The bill directs the Department of Health to evaluate disorders that are on the federal Recommended Uniform Screening Panel (RUSP) as of January 1, 2025, and to determine whether they should be added to Virginia’s screening program based on cost, fiscal impact, and other program considerations. If the Department decides a disorder should be included, it must begin rulemaking within 12 months of the disorder’s addition to the RUSP, and once rulemaking is complete, screening must be implemented within six months if an appropriate test is available.
The bill also establishes a separate process for considering disorders not on the RUSP, requiring the Department to set criteria, timelines, and consultation procedures with the Newborn Screening Advisory Committee and other stakeholders. It further requires annual review of disorders that were previously evaluated and not added, including public input and review of new medical literature, and mandates annual reporting to the General Assembly on the status of the screening program, newly considered disorders, reasons for non-inclusion, and any delays in implementation.
HB433 amends § 32.1-65 of the Code of Virginia, expanding the Department of Health’s duties in administering the newborn screening program. It does not itself add a specific disorder to the screening panel, but it changes the statutory framework for how disorders are evaluated, reconsidered, and added in the future. The bill affects the Department, the Newborn Screening Advisory Committee, newborn screening laboratories, and families of newborns by potentially broadening the set of conditions screened for and by imposing deadlines for review, rulemaking, and implementation.
The available record shows no committee transcript or recorded vote history, so there is no direct evidence of debate or opposition in the provided materials. Based on the bill’s structure, the measure appears to be framed as a public health and administrative modernization bill aimed at keeping Virginia’s screening program aligned with emerging medical standards. The statutory emphasis on timelines, review, and reporting suggests an intent to improve accountability and responsiveness rather than to make a controversial policy shift.
The main points of potential contention are likely to be cost, administrative burden, and the pace of expanding the screening panel. The Department must evaluate fiscal impact and the effect on test fees before adding disorders, which suggests concern about program affordability. Another possible issue is whether Virginia should automatically move toward disorders on the federal RUSP or retain discretion to delay or decline inclusion based on state-specific considerations. Stakeholders such as health officials, laboratory providers, and advocacy groups for affected conditions may differ on how quickly new disorders should be added and how much weight should be given to available testing, FDA-approved treatments, and public input.